Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Membranoproliferative glomerulonephritis (MPGN) is a relatively-rare, immune-mediated kidney
disease. All current therapies are inadequate and MPGN frequently leads to kidney failure.
This study is a 10 patient trial of the monoclonal antibody rituximab for adult patients with
MPGN. Study patients will receive 2 doses of rituximab intravenously on days 1 and 15 and
will then be followed for 1 year.